An open-label study to evaluate the transition of patients with chronic plaque psoriasis from cyclosporine to alefacept
Magliocco, M.A.; Lozano, A.M.; Van Saders, C.; Schuler, K.W.; Gottlieb, A.B.
Journal of Drugs in Dermatology Jdd 6(4): 424-427
2007
ISSN/ISBN: 1545-9616 PMID: 17668540 Document Number: 10893
Eleven patients with well-controlled psoriasis on cyclosporine (Physician's Global Assessment [PGA] of "mild" or better) participated in an open-label study that evaluated a strategy for transition to alefacept. Using this transition strategy, 7 of 11 patients (64%) maintained PGA scores. Quality of life improved or was maintained in all patients. Adverse events and reductions in CD4+ T cell counts were consistent with those seen during alefacept monotherapy.
Document emailed within 1 workday
Related Documents
Koo, J.Y.M.; Bagel, J.; Sweetser, M.T.; Ticho, B.S. 2006: Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study Journal of Drugs in Dermatology: Jdd 5(7): 623-628Vender, R. 2011: An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab Journal of Drugs in Dermatology: Jdd 10(4): 396-402
Abuchar, A.; Vitiello, M.; Ricotti, C.; Grant, A.; Dehesa, L.; Kerdel, F. 2012: Open label study to evaluate the efficacy of re-treatment with etanercept in patients with psoriasis Journal of Drugs in Dermatology: Jdd 11(8): 950-954
Gottlieb, A.B.; Matheson, R.T.; Menter, A.; Leonardi, C.L.; Day, R.M.; Hu, C.; Schafer, P.H.; Krueger, J.G. 2013: Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase Ii open-label study Journal of Drugs in Dermatology: Jdd 12(8): 888-897
Ortonne, J.-P.; Lebwohl, M.; Em Griffiths, C. 2003: Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis European Journal of Dermatology: Ejd 13(2): 117-123
Kircik, L.H. 2011: Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial Journal of Drugs in Dermatology: Jdd 10(8): 878-882
Hudson, C.P.; Kempers, S.; Menter, A.; Papp, K.; Smith, S.; Sofen, H.; Colón, L.E.; Johnson, L.A.; Gottschalk, R. 2011: An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis Cutis 88(4): 201-207
Semmanaselvan, K.; Mukaddam, Q.I.; Naik, M. 2015: An Open Label, Prospective, Single Centre Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Rabeprazole (Enteric-Coated, EC) 20 mg + Domperidone (Sustained Release, SR) 30 mg Capsule in Treatment of Patients with Laryngopharyngeal Reflux Disease Journal of the Association of Physicians of India 63(7): 27-32
Muti, G.F.. 2019: Open-Label, Post-Marketing Study to Evaluate the Performance and Safety of Calcium Hydroxylapatite With Integral Lidocaine to Correct Facial Volume Loss Journal of Drugs in Dermatology: Jdd 18(1): 86-91
Volf, E.M.; Au, S.-C.; Dumont, N.; Scheinman, P.; Gottlieb, A.B. 2012: A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis Journal of Drugs in Dermatology: Jdd 11(3): 341-346
Thawornchaisit, P.; Harncharoen, K. 2007: A comparative study of tar and betamethasone valerate in chronic plaque psoriasis: a study in Thailand Journal of the Medical Association of Thailand 90(10): 1997-2002
Bartenjev, I.; Rogl Butina, M.; Potocnik, M. 2000: Subclinical microbial infection in patients with chronic plaque psoriasis Acta Dermato-Venereologica. Supplementum 2000(211): 17-18
Nevens, F.; Van Vlierberghe, H.; D'Heygere, E.; Delwaide, J.; Adler, M.; Henrion, J.; Lenaerts, A.; Hendlisz, A.; Michielsen, P.; Bastens, B.; Brenard, R.; Laureys, A. 2010: A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients Acta Gastro-Enterologica Belgica 73(2): 223-228
Dube, A.; Deb, A.K.; Das, C.; Padhye, D.; Bhalla, H.; Basu, I.; Bs, M.; Srivastava, P.; Agarwal, R.; Agrawal, R.P.; Singh, R.M.; Kurlekar, U.; Pawar, R.; Shahavi, V.; Srivastava, A. 2018: A Multicentre, Open label, Randomized, Comparative, Parallel Group, Active-controlled, Phase IIi Clinical Trial to Evaluate Safety and Efficacy of Arbekacin Sulphate Injection versus Vancomycin Injection in Patients Diagnosed with MRSA Infection Journal of the Association of Physicians of India 66(12): 47-50
Zoellner, P.; Kapp, H.; Smola, H. 2006: A prospective, open-label study to assess the clinical performance of a foam dressing in the management of chronic wounds Ostomy/Wound Management 52(5): 34-36; 38 40-42 Passim
Kircik, L.H.; Tropmann, C. 2011: Treatment of mild-to-moderate chronic hand dermatitis with clobetasol propionate 0.05% EF foam: results from an open-label study Journal of Drugs in Dermatology: Jdd 10(12): 1398-1402
Gottlieb, A.B.; Gordon, K.B.; Lebwohl, M.G.; Caro, I.; Walicke, P.A.; Li, N.; Leonardi, C.L. 2004: Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis Journal of Drugs in Dermatology: Jdd 3(6): 614-624
Cabras, P.L.; Hardoy, M.J.; Hardoy, M.C.; Carta, M.G. 1999: Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study Journal of Clinical Psychiatry 60(4): 245-248
Strober, B.; Bagel, J.; Lebwohl, M.; Stein Gold, L.; Jackson, J.M.; Chen, R.; Goncalves, J.; Levi, E.; Callis Duffin, K. 2017: Efficacy and Safety of Apremilast in Patients with Moderate Plaque Psoriasis with Lower BSA: Week 16 Results from the UNVEIL Study Journal of Drugs in Dermatology: Jdd 16(8): 801-808
Dammerman, R.; Kim, S.; Adera, M.; Schwarz, A. 2017: A Phase 1, Open-Label, Single Dose Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant Psychopharmacology Bulletin 47(4): 36-40